Send to

Choose Destination
J Invest Dermatol. 2017 Aug;137(8):1638-1645. doi: 10.1016/j.jid.2017.02.977. Epub 2017 Mar 9.

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.

Author information

Innovaderm Research, Incorporated, Montreal, Quebec, Canada. Electronic address:
Montreal Heart Institute Research Center, Université de Montréal, Montreal, Quebec, Canada.
Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, USA.
Montreal Health Innovations Coordinating Center (MHICC), Montreal, Quebec, Canada.
Innovaderm Research, Incorporated, Montreal, Quebec, Canada.
Dr Isabelle Delorme, Incorporated, Drummondville, Quebec, Canada.
Lynderm Research, Incorporated, Markham, Ontario, Canada.


Vascular inflammation is increased in patients with psoriasis. This randomized, double-blind, multicenter study evaluated the effects of tumor necrosis factor-α antagonist adalimumab on vascular inflammation in patients with psoriasis. A total of 107 patients were randomized (1:1) to receive adalimumab for 52 weeks or placebo for 16 weeks followed by adalimumab for 52 weeks. Vascular inflammation was assessed with positron emission tomography-computed tomography. There were no differences in the change from baseline in vessel wall target-to-background ratio (TBR) from the ascending aorta (primary endpoint) (adalimumab: TBR = 0.002, 95% confidence interval [CI] = -0.048 to 0.053; placebo: TBR = -0.002, 95% CI = -0.053 to 0.049; P = 0.916) and the carotids (adalimumab: TBR = 0.031, 95% CI = -0.005 to 0.066; placebo: TBR = 0.018, 95% CI = -0.019 to 0.055; P = 0.629) at week 16 between adalimumab and placebo. After 52 weeks of treatment with adalimumab there was no significant change from start of treatment in TBR from the ascending aorta (TBR = -0.006, 95% CI = -0.049 to 0.038; P = 0.796), but there was an increase in TBR in carotids (TBR = 0.027, 95% CI = 0.000 to 0.054; P = 0.046). This study showed no difference over 16 weeks in vascular inflammation in patients treated with a tumor necrosis factor-α antagonist or placebo and a modest increase in vascular inflammation in carotids after 52 weeks of treatment with adalimumab.


[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center